CA3025366A1 - Methods and compositions for modulating lymphatic vessels in the central nervous system - Google Patents
Methods and compositions for modulating lymphatic vessels in the central nervous system Download PDFInfo
- Publication number
- CA3025366A1 CA3025366A1 CA3025366A CA3025366A CA3025366A1 CA 3025366 A1 CA3025366 A1 CA 3025366A1 CA 3025366 A CA3025366 A CA 3025366A CA 3025366 A CA3025366 A CA 3025366A CA 3025366 A1 CA3025366 A1 CA 3025366A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- vegfr3
- meningeal
- cells
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344164P | 2016-06-01 | 2016-06-01 | |
| US62/344,164 | 2016-06-01 | ||
| PCT/US2017/035285 WO2017210343A1 (en) | 2016-06-01 | 2017-05-31 | Methods and compositions for modulating lymphatic vessels in the central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3025366A1 true CA3025366A1 (en) | 2017-12-07 |
Family
ID=60477853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3025366A Pending CA3025366A1 (en) | 2016-06-01 | 2017-05-31 | Methods and compositions for modulating lymphatic vessels in the central nervous system |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11944665B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3463575B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2019522044A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2017273629B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3025366A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017210343A1 (cg-RX-API-DMAC10.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114949182A (zh) * | 2022-04-07 | 2022-08-30 | 上海大学 | 一种淋巴管生成诱导剂的用途 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11944665B2 (en) | 2016-06-01 | 2024-04-02 | University Of Virginia Patent Foundation | Methods and compositions for modulating lymphatic vessels in the central nervous system |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| WO2020018461A1 (en) * | 2018-07-16 | 2020-01-23 | The University Of Virginia Patent Foundation | Compositions and methods of diagnosis and treatment for neurological diseases |
| KR20210100086A (ko) * | 2018-10-04 | 2021-08-13 | 유니버시티 오브 로체스터 | 혈장 오스몰농도 조작에 의한 글림프 전달의 개선 |
| KR20210093972A (ko) | 2018-11-16 | 2021-07-28 | 예일 유니버시티 | 뇌 및 cns 종양 요법을 위한 수막 림프계 맥관구조의 조작 |
| US20240050529A1 (en) * | 2019-10-07 | 2024-02-15 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
| US20230067811A1 (en) | 2020-01-24 | 2023-03-02 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
| EP4608432A4 (en) * | 2022-10-25 | 2026-08-12 | Inst For Basic Science Ibs | EXTRACTION METHODS TO ENABLE CEREBRAL-SPINAL FLUID DRAINAGE |
| WO2024173675A1 (en) * | 2023-02-16 | 2024-08-22 | University Of Rochester | Improving glymphatic-lymphatic efflux |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4642303B2 (ja) | 1999-09-21 | 2011-03-02 | アンジェスMg株式会社 | 脳血管障害のための遺伝子治療 |
| US20040214766A1 (en) * | 2001-10-01 | 2004-10-28 | Kari Alitalo | VEGF-C or VEGF-D materials and methods for treatment of neuropathologies |
| CN1886149A (zh) | 2003-09-23 | 2006-12-27 | 路德维格癌症研究院 | Vegf-c或vegf-d物质及刺激神经干细胞的方法 |
| US9415090B2 (en) * | 2011-06-01 | 2016-08-16 | Universität Heidelberg | VEGF-D/VEGFR2/3-mediated regulation of dendrites |
| US8852936B2 (en) * | 2012-09-21 | 2014-10-07 | Laurantis Pharma Oy | Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery |
| WO2017190074A1 (en) | 2016-04-28 | 2017-11-02 | The University Of Chicago | Lymphangiogenesis for therapeutic immunomodulation |
| US11944665B2 (en) | 2016-06-01 | 2024-04-02 | University Of Virginia Patent Foundation | Methods and compositions for modulating lymphatic vessels in the central nervous system |
| KR20210093972A (ko) | 2018-11-16 | 2021-07-28 | 예일 유니버시티 | 뇌 및 cns 종양 요법을 위한 수막 림프계 맥관구조의 조작 |
-
2017
- 2017-05-31 US US16/306,483 patent/US11944665B2/en active Active
- 2017-05-31 AU AU2017273629A patent/AU2017273629B2/en active Active
- 2017-05-31 EP EP17807427.4A patent/EP3463575B1/en active Active
- 2017-05-31 JP JP2019515772A patent/JP2019522044A/ja active Pending
- 2017-05-31 WO PCT/US2017/035285 patent/WO2017210343A1/en not_active Ceased
- 2017-05-31 CA CA3025366A patent/CA3025366A1/en active Pending
-
2021
- 2021-12-21 JP JP2021207229A patent/JP2022031368A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114949182A (zh) * | 2022-04-07 | 2022-08-30 | 上海大学 | 一种淋巴管生成诱导剂的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| US11944665B2 (en) | 2024-04-02 |
| JP2022031368A (ja) | 2022-02-18 |
| EP3463575B1 (en) | 2025-03-26 |
| US20190269758A1 (en) | 2019-09-05 |
| AU2017273629B2 (en) | 2023-06-08 |
| EP3463575A1 (en) | 2019-04-10 |
| JP2019522044A (ja) | 2019-08-08 |
| EP3463575A4 (en) | 2020-01-29 |
| AU2017273629A1 (en) | 2018-12-13 |
| WO2017210343A1 (en) | 2017-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017273629B2 (en) | Methods and compositions for modulating lymphatic vessels in the central nervous system | |
| Reichenbach et al. | Inhibition of Stat3‐mediated astrogliosis ameliorates pathology in an Alzheimer's disease model | |
| Matsushita et al. | Diffuse and persistent blood–spinal cord barrier disruption after contusive spinal cord injury rapidly recovers following intravenous infusion of bone marrow mesenchymal stem cells | |
| US20200345812A1 (en) | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists | |
| JP6920324B2 (ja) | 神経細胞の損失予防及び再生の効能を有するペプチド及びこれを含む組成物 | |
| ES2546093T3 (es) | VEGF para utilizar en el tratamiento de trastornos del sistema nervioso central | |
| Osterstock et al. | Sustained alterations of hypothalamic tanycytes during posttraumatic hypopituitarism in male mice | |
| AU2020363372A1 (en) | Modulating lymphatic vessels in neurological disease | |
| ES2825101T3 (es) | Composiciones y métodos para el tratamiento de trastornos neuropsiquiátricos usando un agonista del receptor de la endotelina B | |
| Feng et al. | Meningeal lymphatics as a therapeutic target for neurodegenerative disorders | |
| AU2011314074B2 (en) | ND2 peptides and methods of treating neurological disease | |
| CN117202911A (zh) | 包含作为活性成分的刺五加苷b的用于治疗神经炎症的药物组合物 | |
| Xu et al. | Increased expression of placental growth factor in patients with temporal lobe epilepsy and a rat model | |
| US20260132176A1 (en) | Compositions and methods for treating neurodegenerative disease | |
| US20240207362A1 (en) | Extracranial Methods For Facilitating Cerebrospinal Fluid Drainage | |
| Lengning | Role of neuroblast-derived signals in post-stroke neurovascular remodeling | |
| Wang et al. | The liver and muscle secreted Hfe2-protein maintains blood brain barrier integrity | |
| Mandler | Characterisation of neuropathologic alterations following active immunotherapy against Aβ | |
| Correa et al. | Intranasal delivery of full-length anti-Nogo-A antibody | |
| 류정화 | A study on the attenuating effects of neuregulin-1 on cognitive function impairments and its action mechanisms in an Alzheimers disease animal model | |
| Hawk | Retrograde influences of peripheral nerve injury on uninjured neurons | |
| Bartel | Central glial responses following peripheral injury to the chorda tympani gustatory nerve | |
| WO2017202814A1 (en) | Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220526 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240909 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250109 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251117 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260119 |